Blood

Vol. 146, Issue 4 Issue 4 2025
16
Articles

Articles in this Issue

Postimmunotherapy lineage switch: where to from here?

James A. Kuzich Jul 24, 2025 pp. 400-402 10.1182/blood.2025029260

NKG2D-mediated cytotoxicity of CD4 cytotoxic T cells in multiple myeloma

Sojeong Kim, Jeong-Eun Kwak, June-Young Koh et al. Jul 24, 2025 pp. 456-470 10.1182/blood.2024025875

Abstract Emerging evidence indicates that CD4+ T cells contribute to antitumor immunity beyond their traditional roles as helpers or regulators. However, the specific subset of CD4+...

Relationship between immunogenicity and protein structure at amino acid substitution sites of blood group antigens

John G. Howe, Gary Stack Jul 24, 2025 pp. 504-517 10.1182/blood.2024025071

Abstract Polypeptide blood group antigens, many of which are created by single exofacial amino acid substitutions, have varying immunogenicities. Why some amino acid substitutions ar...

Differentiation-dependent EBF1 activity determines <i>CD22</i> transcription and leukemia sensitivity to inotuzumab ozogamicin

Carolin S. Escherich, Zhenhua Li, Kelly R. Barnett et al. Jul 24, 2025 pp. 471-481 10.1182/blood.2024028215

Abstract Inotuzumab ozogamicin (InO) is an antibody-calicheamicin conjugate with high efficacy in lymphoid malignancies. It targets the B-cell surface protein CD22, which is expresse...

Predicting blood group antigens: accessible or not?

Piers Walser Jul 24, 2025 pp. 409-410 10.1182/blood.2025029154

Inhibiting JAK1: lowering CRS, CAR stays on track

Akiva Diamond, Leo Luznik Jul 24, 2025 pp. 399-400 10.1182/blood.2025029068

Shear-dependent platelet aggregation by ChAdOx1 nCoV-19 vaccine: a novel biophysical mechanism for arterial thrombosis

Yiyao Catherine Chen, Naveen Eugene Louis Richard Louis, Angela Huang et al. Jul 24, 2025 pp. 496-503 10.1182/blood.2024027675

Abstract Rare thrombotic events associated with ChAdOx1 nCoV-19 (ChAdOx1) vaccination have raised concerns; however, the underlying mechanisms remain elusive. Here, we report a novel...

Cytolytic helper T cells: a new addition to myeloma immunity

Tom Cupedo Jul 24, 2025 pp. 402-403 10.1182/blood.2025028916

Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 study

Matthew J. Frigault, Richard T. Maziarz, Jae H. Park et al. Jul 24, 2025 pp. 422-436 10.1182/blood.2024026586

Abstract Cytokine release syndrome (CRS) and immune effector cell (IEC)–associated neurotoxicity syndrome (ICANS) are common complications after IEC therapy for hematologic malignanc...

Dissecting JAK2V617F’s double life with and without MPL

Isabelle Plo, Caroline Marty Jul 24, 2025 pp. 406-408 10.1182/blood.2025029479

Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria throughout clinical trials: from definition to clinical practice

Bruno Fattizzo, Francesco Versino, Wilma Barcellini Jul 24, 2025 pp. 411-421 10.1182/blood.2024027574

Abstract Breakthrough hemolysis (BTH) is the hemolytic exacerbation occurring in a patient with paroxysmal nocturnal hemoglobinuria (PNH) on treatment with anticomplement therapies....

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Sara K. Silbert, Alexander W. Rankin, Chloe N. Hoang et al. Jul 24, 2025 pp. 437-455 10.1182/blood.2024026655

Abstract Lineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is a...

Hematological aspects of colchicine poisoning

Pierre Arnautou, Sarah Bugier Jul 24, 2025 pp. 518-518 10.1182/blood.2025029558

Delineating <i>Mpl</i>-dependent and -independent phenotypes of <i>Jak2</i> V617F–positive MPNs in vivo

Nicolas Papadopoulos, Audrey Nédélec, Yacine Rahmani et al. Jul 24, 2025 pp. 482-495 10.1182/blood.2024026711

Abstract The Jak2 V617F mutation stands as the main driver of myeloproliferative neoplasms (MPNs) by constitutively activating signaling through several type I cytokine receptors, na...

Adenovirus holds the platelet in flow

Renhao Li Jul 24, 2025 pp. 408-409 10.1182/blood.2025029446

Targeting B-cell identity: how EBF1 modulates InO response

Lorenz Bastian Jul 24, 2025 pp. 404-405 10.1182/blood.2025029476

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page